Pfizer Inc. (PFE)
 NYSE: PFE · Real-Time Price · USD
 24.57
 +0.28 (1.15%)
  Oct 31, 2025, 2:50 PM EDT - Market open
 
 Revenue
 Financials in millions USD. Fiscal year is January - December.
 Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 
|---|
| Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 
|---|
|  | 29.21B | 30.14B |  |  |  |  | 
|  | 17.09B | 16.65B |  |  |  |  | 
|  | 16.25B | 15.61B |  |  |  |  | 
| Global Pharmaceuticals Business (Biopharma) Revenue | 62.55B | 62.40B |  |  |  |  | 
| Business Innovation (Pfizer CentreOne) Revenue | 1.20B | 1.15B |  |  |  |  | 
|  | 86.00M | 81.00M |  |  |  |  | 
|  | 63.83B | 63.63B |  |  |  |  | 
Revenue by Geography
 Financials in millions USD. Fiscal year is January - December.
 Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 
|---|
| Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 
|---|
|  | 38.55B | 38.69B |  |  |  |  | 
| Developed Markets Revenue | 16.27B | 16.06B |  |  |  |  | 
| Emerging Markets Revenue (Post-FY2023 Reporting) | 9.01B | 8.88B |  |  |  |  | 
|  | - | - |  |  |  |  | 
|  | 63.83B | 63.63B |  |  |  |  | 
Revenue by Geography 2
 Financials in millions USD. Fiscal year is January - December.
 Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 
|---|
| Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 
|---|
|  | 38.55B | 38.69B |  |  |  |  | 
|  | 63.83B | 63.63B |  |  |  |  | 
Revenue by Geography 3
 Financials in millions USD. Fiscal year is January - December.
 Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 
|---|
| Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 
|---|
|  | 38.55B | 38.69B |  |  |  |  | 
|  | - | - |  |  |  |  | 
| Developed Rest of World Revenue | - | - |  |  |  |  | 
|  | - | - |  |  |  |  | 
|  | 25.28B | 24.94B |  |  |  |  | 
|  | 63.83B | 63.63B |  |  |  |  | 
EBT
 Financials in millions USD. Fiscal year is January - December.
 Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 
|---|
| Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 
|---|
| Global Pharmaceuticals Business (Biopharma) Earnings | 28.65B | 28.14B |  |  |  |  | 
| Other Business Activities Earnings | -6.61B | -7.38B |  |  |  |  | 
Key Performance Indicators
 Financials in millions USD. Fiscal year is January - December.
 Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 
|---|
| Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 
|---|
| Comirnaty Direct Sales and Alliance Revenue | 5.75B | 5.35B |  |  |  |  | 
| Eliquis Alliance Revenue and Direct Sales | 7.38B | 7.37B |  |  |  |  | 
|  | - | - |  |  |  |  | 
|  | 4.35B | 5.72B |  |  |  |  | 
|  | 6.40B | 6.41B |  |  |  |  | 
| Nurtec ODT/Vydura Revenue | 1.34B | 1.26B |  |  |  |  | 
|  | 828.00M | 755.00M |  |  |  |  | 
|  | 6.09B | 5.45B |  |  |  |  | 
|  | 1.12B | 1.17B |  |  |  |  | 
|  | 4.21B | 4.37B |  |  |  |  | 
|  | - | - |  |  |  |  | 
| Internal Medicine Revenue | - | - |  |  |  |  | 
|  | - | - |  |  |  |  | 
| Inflammation & Immunology Revenue | - | - |  |  |  |  | 
|  | - | - |  |  |  |  | 
Updated Aug 5, 2025. Data Source: 
Fiscal.ai.